News | June 22, 2015

IBA, Philips India to Introduce Proton Therapy Cancer Treatment in India

Agreement will create country’s first proton center while expanding research, development and marketing opportunities

IBA, Philips India, Apollo Proton Therapy Center, first in India

June 22, 2015 - IBA (Ion Beam Applications S.A.) and Royal Philips announced the signing of an exclusive agreement to enhance access to proton therapy in India. The alliance combines IBA's strengths in proton therapy and Philips' expertise in clinical informatics and innovative imaging techniques for therapy planning and guidance.

Leveraging proton therapy and high-quality imaging offers the potential to increase confidence in the diagnosis and treatment of cancer, reduce short- and long-term side-effects and potentially enhance the quality of life of the patient before, during and after treatment. Advanced magnetic resonance imaging (MRI), positron emission tomography (PET) and computed tomography (CT) imaging technologies will help physicians better target proton beam delivery to destroy cancer cells whilst avoiding healthy tissue.

This agreement builds upon the collaboration between IBA and Philips India, which started in 2013, to build the Apollo Proton Therapy Center, the first proton therapy center in India.

Proton therapy is an important addition to cancer treatment in India given that the incidence of cancer is 70-90 per 100,000 people, with children comprising nearly 5 percent of these patients. Proton therapy is considered to be one of the most advanced treatments available in the fight against cancer. With the precision that proton therapy offers, it is possible to target the tumor more effectively while limiting the side effects of the treatment. Protons deposit the majority of their energy within a precisely controlled zone, directly in the tumor while limiting the impact on healthy tissues surrounding the tumor.

The exclusive Philips-IBA agreement for India follows the framework agreement that Philips and IBA signed in September 2014. The framework agreement comprises research and development, marketing and sales of imaging and therapy solutions in oncology. The collaboration also enables both organizations to mutually leverage technologies and solutions: IBA benefits from Philips diagnostic imaging products offered to oncology care centers, while Philips will leverage IBA proton therapy solutions within its offering for customers in select markets around the world. As part of the framework agreement, Philips and IBA have already signed multiple country-specific collaboration agreements, each optimized for the local market needs.

For more information: www.iba-worldwide.com

Related Content

Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
Varian Acquires Mobius Medical Systems
News | Quality Assurance (QA) | February 06, 2018
February 6, 2018 – Varian announced it has acquired privately-held Mobius Medical Systems, a...
Microbubbles Make Breast Cancer More Susceptible to Radiation Therapy
News | Women's Health | February 01, 2018
February 1, 2018 – Injecting breast cancer with oxygen-filled microbubbles makes tumors three-times more sensitive to
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
RayStation Selected for India’s First Proton Center
News | Proton Therapy | February 01, 2018
February 1, 2018 – Apollo Hospitals, Asia´s foremost integrated healthcare provider, has selected RayStation for a ne
Varian Signs Agreement to Acquire Sirtex
News | Radiation Therapy | January 31, 2018
January 31, 2018 — Varian Medical Systems announced it has signed an agreement to acquire all the outstanding shares
RayStation Selected for London's Charing Cross Hospital and Hammersmith Hospital
News | Treatment Planning | January 30, 2018
Imperial College Healthcare NHS Trust in London, U.K., has chosen RayStation as the sole treatment planning system for...
Small-Cell Lung Cancer Patients Face Barriers to Standard-of-Care Treatment
News | Lung Cancer | January 29, 2018
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the...
Overlay Init